TCGA-P3-A5QF-01A-11R-A28V-07
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 0.075342466
- sex
- male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- E2F_TARGETS+0.530
- MYC_TARGETS_V1+0.490
- OXIDATIVE_PHOSPHORYLATION+0.410
- G2M_CHECKPOINT+0.390
- DNA_REPAIR+0.380
- MTORC1_SIGNALING+0.360
- FATTY_ACID_METABOLISM+0.340
- MYC_TARGETS_V2+0.290
- CHOLESTEROL_HOMEOSTASIS+0.280
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.260
Top 10 suppressed
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.600
- ANGIOGENESIS-0.470
- TGF_BETA_SIGNALING-0.380
- APICAL_JUNCTION-0.370
- HEDGEHOG_SIGNALING-0.370
- MYOGENESIS-0.360
- WNT_BETA_CATENIN_SIGNALING-0.340
- NOTCH_SIGNALING-0.330
- INFLAMMATORY_RESPONSE-0.310
- UV_RESPONSE_DN-0.310
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-BA-A6DL-01A-21R-A30B-07 | — | — | 0.922 |
| 2 | SRR8518448 | — | C | 0.903 |
| 3 | SRR2932846 | — | — | 0.901 |
| 4 | C3L-00415 | — | cohortSQ1 | 0.889 |
| 5 | TCGA-22-5491-01A-01R-1635-07 | — | cohortSQ2 | 0.889 |
| 6 | TCGA-39-5036-01A-01R-1443-07 | — | cohortSQ2 | 0.887 |
| 7 | TCGA-BA-A4IG-01A-11R-A266-07 | — | — | 0.877 |
| 8 | ERR2208932 | — | — | 0.874 |
| 9 | BSR_14_0066_A2_S94 | — | C | 0.873 |
| 10 | 0acddbbc-6b74-4fdd-903d-f5ec9bfd8514 | — | — | 0.869 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 24 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| E2F_TARGETS | 0.530 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.490 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.410 | Remibrutinib | — uncovered |
| G2M_CHECKPOINT | 0.390 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.380 | Idelalisib | — uncovered |
| MTORC1_SIGNALING | 0.360 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.340 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.290 | Idelalisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.280 | Remibrutinib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.260 | Inavolisib | — uncovered |
| PEROXISOME | 0.250 | Idelalisib | — uncovered |
| SPERMATOGENESIS | 0.210 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.200 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.190 | Inavolisib | — uncovered |
| UV_RESPONSE_UP | 0.180 | Idelalisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.180 | Inavolisib | — uncovered |
| P53_PATHWAY | 0.170 | Idelalisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.130 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.060 | Idelalisib | — uncovered |
| ANDROGEN_RESPONSE | 0.050 | Inavolisib | — uncovered |